Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew H Ko

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Investigational New Drugs|June 2, 2011
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinomaAndrew H Ko, Hagop Youssoufian, Jayne Gurtler, et al.
Investigational New Drugs|April 2, 2008
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Andrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
American Journal of Clinical Oncology|December 5, 2021
Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort AnalysisShohei Burns, Maya Vella, Alan Paciorek, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2010
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancerAndrew H Ko, Alan P Venook, Emily K Bergsland, et al.
American Journal of Clinical Oncology|July 29, 2014
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With BevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
AJR. American Journal of Roentgenology|August 1, 2018
Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRIZhen J Wang, Spencer Behr, Martin V Consunji, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 2, 2023
Hyperpolarized <sup>13</sup>C Metabolic MRI of Patients with Pancreatic Ductal AdenocarcinomaJeremy W Gordon, Hsin-Yu Chen, Tanner Nickles, et al.
The Oncologist|September 10, 2021
Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic AdenocarcinomaEvan J Walker, Dena Goldberg, Kelly M Gordon, et al.
Cancer|March 18, 2014
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
The American Journal of Surgical Pathology|September 14, 2018
Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?Sunhee S Kim, Andrew H Ko, Eric K Nakakura, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Investigational New Drugs|June 2, 2011
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinomaAndrew H Ko, Hagop Youssoufian, Jayne Gurtler, et al.
Investigational New Drugs|April 2, 2008
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Andrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
American Journal of Clinical Oncology|December 5, 2021
Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort AnalysisShohei Burns, Maya Vella, Alan Paciorek, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2010
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancerAndrew H Ko, Alan P Venook, Emily K Bergsland, et al.
American Journal of Clinical Oncology|July 29, 2014
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With BevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
AJR. American Journal of Roentgenology|August 1, 2018
Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRIZhen J Wang, Spencer Behr, Martin V Consunji, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 2, 2023
Hyperpolarized <sup>13</sup>C Metabolic MRI of Patients with Pancreatic Ductal AdenocarcinomaJeremy W Gordon, Hsin-Yu Chen, Tanner Nickles, et al.
The Oncologist|September 10, 2021
Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic AdenocarcinomaEvan J Walker, Dena Goldberg, Kelly M Gordon, et al.
Cancer|March 18, 2014
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
The American Journal of Surgical Pathology|September 14, 2018
Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?Sunhee S Kim, Andrew H Ko, Eric K Nakakura, et al.
Pageof 10